• Home
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • 2.0 LPBI Brochure
  • Coronavirus, SARS-CoV-2 Portal
  • Knowledge PORTALS System (KPS)
  • Journal PharmaceuticalIntelligence.com
  • 2020-21 VISTA 1.0 LPBI
  • LPBI Group’s History
  • 2020-21 VISION – 2.0 LPBI
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder
  • Funding, Deals & Partnerships
  • LPBI Group News
  • CALENDAR
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2020 Summer Internship Portal
  • 2021 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • Blockchain Transactions Network Ecosystem
  • Contact Us
  • 1.0 LPBI Brochure

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal – http://PharmaceuticalIntelligence.com

Feeds:
Posts
Comments

Joel Shertok, PhD, Member of The Board, Business Development and Process Designer of a Global AI-based External Relations Prospecting System for LPBI Group

Joel Shertok, PhD, Member of The Board, Business Development and Process Designer of a Global AI-based External Relations Prospecting System for LPBI Group

UPDATED on 11/9/2020

Selected Projects:

1. BOT-based Prospective System based on 12 Economic Segments 

Under exploration: New BOT Vendor

Opportunities Map in the Acquisition Arena

  • Prepare one prototype for industry of your choice
  • Scale up to 6 industries – get Aviva’s input in selection

2. IB communications

BIO

Dr. Joel Shertok

jshertok@processindconsultants.com  

302-562-9759

 

Dr. Joel Shertok is a senior level executive who has over 40 years of experience in the Chemical Process and Materials industries. His track record is characterized by: merger and acquisition experience, development of new product lines, creation of new business ventures, creation/motivation of new business teams, and international investigations of novel technologies.

Previously, Dr. Shertok has been a Research Fellow at Rochester Institute of Technology. He has held senior technical and managerial positions at Rochester Midland Corporation (formulated products and sanitizers, Graver Technologies (filtration and purification), Pall-Gelman Corporation (membrane filtration and water purification), Amoco Corporation (Carbon fiber composites and BioTechnology), and Union Carbide (specialty chemicals).

Dr. Shertok holds numerous patents in membrane technology, carbon purification, and in industrial food service cleaners. He is currently President of Process Industries Consultants, a chemical engineering consulting firm located in Newark, Delaware.

Curriculum Vitae

Responsibilities

Verticals:

(1) Chemical Industry

(2) Financials & Insurance: Health Care

(3) Biotech

(4) Private Equity

Business Development responsibilities @LPBI:

(1) All Documentation Artifacts expected by External Relation

(2) Client facing engagement with External relations: Information Syndication

(3) Development of a Bot-based Global Prospecting System for LPBI

3.1 applications on ALA’s 7,300

3.2 applications on JTS’s 1st degree connections on LinkedIn

(4) LPBI’s LEAD all efforts with IB

(5) LPBI’s LEAD for all Partnerships:

5.1 LPBI J-V (30%) with ABI-Lab (70%)

5.2 BurstIQ

5.3 Agreements with Wolfram Machine Learning Approach https://www.wolfram.com/featureset/machine-learning/ 

Plan for Business Development Activity at 1.0 LPBI 4Q 2020

  • 1,4,5, ABOVE

Roles on 2.0 LPBI Group’s TNS #1,2,3,4,5,6 https://pharmaceuticalintelligence.com/vision/

  • 2,3,5, ABOVE

TNS #1: See 5.3, above – TEXT Analysis on our CONTENTS: NLP, ML, AI – INSIGHTS MEAN VALUE and Up-selling content = NEW WARES to be brought to the market

TNS #2: See 5.2, above, Blockchain Transactions and broadcasting to communities in the Health Care Sector – THE ONLY WAY TO MONETIZE our content by narrow casting to Health Care Communities: BustIQ – lined them up and are willing to build the Front End

TNS #3: Podcasts – will not be a Money maker – will be a Reputation Builder – very important in Pharmaceutical MEDIA

TNS #4: Conversion e-Books to Audio and Articles to SoundCloud Audio files – Text to Audio  [SEE New Yorker] – HAS POTENTIAL

TNS #5: See 5.1, above Joint venture with Dr. Nir for Drug Discovery: 

TNS #6:  e-Books Translations into Japanese, Spanish, Russian 

Plan for Business Development Activity at 2.0 LPBI 1Q 2021

  • See 5.1, 5.2, 5.3, above

 

Publications with Leaders in Pharmaceutical Business Intelligence (LPBI) Group

 

Why We Can’t Foresee the Pandemic’s Long-Term Effects jshertok
COVID-19, Economic Impact of Coronavirus Pandemic, Population Health Management, Population Health Management, Genetics & Pharmaceutical, U.S. Employment-to-Population Ratio
Published
2020/07/03 at 7:20 pm
The COVID-19 Recovery will be digital: A plan for the First 90 Days jshertok
COVID-19, Economic Impact of Coronavirus Pandemic, Population Health Management, Population Health Management, Genetics & Pharmaceutical, U.S. Employment-to-Population Ratio
Published
2020/05/16 at 12:08 pm
The Impact Of The Coronavirus Crisis On Mergers And Acquisitions jshertok
COVID-19, Economic Impact of Coronavirus Pandemic, Population Health Management
Published
2020/04/17 at 9:30 am
When Will Life Be Normal Again? We Just Don’t Know jshertok
COVID-19, Economic Impact of Coronavirus Pandemic, Population Health Management
Published
2020/04/13 at 10:15 am
Economic Implications of the Coronavirus jshertok
COVID-19, Economic Impact of Coronavirus Pandemic
Published
2020/03/21 at 2:04 pm
Will the Coronavirus Permanently Change Our Way of Working? jshertok
COVID-19, Economic Impact of Coronavirus Pandemic, Population Health Management, Genetics & Pharmaceutical, Virus Infective Acute Respiratory Syndrome: SARS-CoV
Published
2020/03/19 at 2:44 pm
The Problem and Challenges of Commercialization jshertok Commercialization, Drug Development Process, Pharmacovigilance, Rapid automation of plasma protein pools Published
2019/12/23 at 1:02 pm

Share this:

  • Twitter
  • Facebook
  • LinkedIn
  • Print
  • Email

Like this:

Like Loading...

  • Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 2,063 other followers

  • Recent Posts

    • National Resilience, Inc. is a first-of-its-kind manufacturing and technology company dedicated to broadening access to complex medicines and protecting biopharmaceutical supply chains against disruption – the Acquisition of Two Premier Biologics Manufacturing Facilities: Boston and in Ontario, Canada March 4, 2021
    • 19 of the 49 New Therapeutic Molecular Entities FDA approved in 2020 — as well as a new Cell-based therapy — are Personalized Medicines March 2, 2021
    • Happy 80th Birthday: Radioiodine (RAI) Theranostics: Collaboration between Physics and Medicine, the Utilization of Radionuclides to Diagnose and Treat: Radiation Dosimetry by Discoverer Dr. Saul Hertz, the early history of RAI in diagnosing and treating Thyroid diseases and Theranostics March 2, 2021
    • 2.0 LPBI is a Very Unique Organization  March 2, 2021
    • FDA emergency use authorization would bring the public a third vaccine for the novel coronavirus – J&J single vaccine – Authorized on 2/28/2021 March 1, 2021
    • Medical Device Representatives coach Surgeons in the Operating Rooms March 1, 2021
    • 2021 Virtual World Medical Innovation Forum, Mass General Brigham, Gene and Cell Therapy, VIRTUAL May 19–21, 2021 February 26, 2021
    • Inhibitory CD161 receptor recognized as a potential immunotherapy target in glioma-infiltrating T cells by single-cell analysis February 20, 2021
    • First single-course ‘curative’ CRISPR Shot by Intellia rivals Alnylam, Ionis and Pfizer February 19, 2021
    • Contribution of Nervous System Functional Deterioration to late-life Mortality: The Role Neurofilament light chain (NfL) a Blood Biomarker for the Progression of Neurological Diseases and its Correlation to Age and Life Expectancy February 19, 2021
  • Archives

  • Categories

  • Meta

    • Register
    • Log in
    • Entries feed
    • Comments feed
    • WordPress.com
    • 2012pharmaceutical
    • Amandeep Kaur
    • Aashir Awan, Phd
    • Adina Hazan
    • Alan F. Kaul, PharmD., MS, MBA, FCCP
    • alexcrystal6
    • anamikasarkar
    • apreconasia
    • aviralvatsa
    • David Orchard-Webb, PhD
    • danutdaagmailcom
    • Demet Sag, Ph.D., CRA, GCP
    • Daniel Menzin
    • Dror Nir
    • dsmolyar
    • evelinacohn
    • Gail S Thornton
    • Irina Robu
    • jayzmit48
    • jdpmd
    • jshertok
    • kellyperlman
    • Ed Kislauskis
    • larryhbern
    • Madison Davis
    • marzankhan
    • megbaker58
    • ofermar2020
    • Dr. Pati
    • pkandala
    • Rosalind Codrington, PhD
    • ritusaxena
    • Rick Mandahl
    • sjwilliamspa
    • stuartlpbi
    • Dr. Sudipta Saha
    • tildabarliya
    • zraviv06
    • zs22

Blog at WordPress.com.

WPThemes.


Cancel

 
Loading Comments...
Comment
    ×
    loading Cancel
    Post was not sent - check your email addresses!
    Email check failed, please try again
    Sorry, your blog cannot share posts by email.
    %d bloggers like this: